Jon Holmlund

2.4k citations

55 papers · 1.7k indexed · h-index 24

Oncology top 5%
- Lung Cancer Research Studies 6
- Colorectal Cancer Treatments and Studies 5
- Cancer Treatment and Pharmacology 5
Molecular Biology top 10%
- Cancer therapeutics and mechanisms 4
Cancer Research top 10%
Genetics top 10%
Hematology top 10%
Pulmonary and Respiratory Medicine
- Oral health in cancer treatment 11
- Lung Cancer Treatments and Mutations 8
Otorhinolaryngology
- Head and Neck Cancer Studies 11
Radiology, Nuclear Medicine and Imaging
- Radiopharmaceutical Chemistry and Applications 6

Co-authors: Richard S. Geary Andrew Dorr T. Jesse Kwoh F. Andrew Dorr John Nemunaitis Brett P. Monia Casey Cunningham Mario Sznol
Cited by: Oncology Molecular Biology Cancer Research
Journals: Journal of Clinical Oncology (18 papers)International Journal of Radiation Oncology*Biology*Physics (8 papers)Cancer (2 papers)
Partner nations: United States Canada Russia

In The Last Decade

Jon Holmlund

53 papers receiving 1.7k citations

Peers

Countries citing papers authored by Jon Holmlund

Since Specialization

Citations

This map shows the geographic impact of Jon Holmlund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jon Holmlund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jon Holmlund more than expected).

Fields of papers citing papers by Jon Holmlund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jon Holmlund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jon Holmlund. The network helps show where Jon Holmlund may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jon Holmlund, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jon Holmlund Line = papers co-authored together Jon Holmlund links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	ROMAN: Phase 3 trial of avasopasem manganese (GC4419) for severe oral mucositis (SOM) in patients receiving chemoradiotherapy (CRT) for locally advanced, nonmetastatic head and neck cancer (LAHNC). Journal of Clinical Oncology ·Carryn M. Anderson,Christopher M. Lee,محمد علي سليمان أبوبكر,Gary V. Walker,Neal Dunlap,Voichita Bar‐Ad,Douglas A. Miller,Christine Kirlew,Seyed Zahra Valedsaravi,Atharv Kulkarni,F. Vincent,Brian C. Muzyka,Amanda Gillespie-Twardy,Stephen T. Sonis,Jon Holmlund,Deborah Saunders	2022	9
2	Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC) International Journal of Radiation OncologyBiologyPhysics ·Sarah E. Hoffe,Jessica M. Frakes,Todd A. Aguilera,Brian G. Czito,Manisha Palta,Nitza Nater Arvelo,Charles Schweizer,Lauren E. Colbert,Shalini Moningi,Manoop S. Bhutani,Shubham Pant,Hai Chean Yow,Rebecca S. Tidwell,Peter F. Thall,Ying Yuan,Elizabeth Charlotte Moser,Jon Holmlund,Joseph M. Herman,Cullen M. Taniguchi	2020	12
3	Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer. Journal of Clinical Oncology ·Elizabeth Charlotte Moser,Sarah E. Hoffe,Jessica M. Frakes,Todd A. Aguilera,Kazushi TAMANO,Lauren E. Colbert,Shalini Moningi,Ching‐Wei D. Tzeng,Peter F. Thall,Shubham Pant,Manoop S. Bhutani,Nitza Nater Arvelo,Jon Holmlund,Joseph M. Herman,Cullen M. Taniguchi	2020	0
4	Phase 1b/2a Trial of the Superoxide Dismutase Mimetic GC4419 to Reduce Chemoradiotherapy-Induced Oral Mucositis in Patients With Oral Cavity or Oropharyngeal Carcinoma International Journal of Radiation OncologyBiologyPhysics ·Carryn M. Anderson,Stephen T. Sonis,Christopher M. Lee,Douglas R. Adkins,Bryan G. Allen,Wenqing Sun,Sanjiv S. Agarwala,Bao Miguel,Yuhchyau Chen,Weining Zhen,Diane R. Mould,Jon Holmlund,D. B. Kirby,John M. Buatti	2017	64
5	Double-Blind, Placebo-Controlled, Randomized Phase 2 Study of the Proapoptotic Agent AT-101 Plus Docetaxel, in Second-Line Non-small Cell Lung Cancer Journal of Thoracic Oncology ·Neal Ready,Nina Karaseva,С. В. Орлов,Alexander Luft,Alexander Harpke,Jon Holmlund,Brian Wood,Lance Leopold	2011	74
6	Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer Annals of Oncology ·Guru Sonpavde,В. Б. Матвеев,John M. Burke,J. R. Caton,Mark T. Fleming,Thomas E. Hutson,Matt D. Galsky,William L. Berry,Petr Karlov,Jon Holmlund,Brian Wood,Matthew Brookes,L. Leopold	2011	118
7	Efficacy and toxicity of the antisense oligonucleotide aprinocarsendirected against protein kinase C-α delivered as a 21-day continuousintravenous infusion in patients with recurrent high-grade astrocytomas Neuro-Oncology ·Stuart A. Grossman,Jane Β. Alavi,Jeffrey G. Supko,Kathryn A. Carson,A S Kashyap,F. Andrew Dorr,John S. Grundy,Jon Holmlund	2005	44
8	A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-α administered as a 24-hour weekly infusion schedule in patients with advanced cancer Investigational New Drugs ·Ranjana H. Advani,Bert L. Lum,George A. Fisher,Joanne Halsey,Richard S. Geary,Jon Holmlund,T. Jesse Kwoh,F. Andrew Dorr,Branimir I. Šikić	2005	32
9	Phase II study of ISIS 3521, an antisense oligodeoxynucleotide to protein kinase C alpha, in patients with previously treated low-grade non-Hodgkin's lymphoma Annals of Oncology ·Sheela Rao,David Watkins,David Cunningham,DJ Dunlop,Peter Johnson,Peter J. Selby,Barry W. Hancock,CD Fegan,Dominic Culligan,Stephen Schey,T. C. M. Morris,Toshko Lissitchkov,Jennifer Oliver,Jon Holmlund	2004	37
10	A Phase II Trial of ISIS 3521 in Patients with Metastatic Colorectal Cancer Clinical Colorectal Cancer ·John L. Marshall,Mathias Sippel,Michael D. Johnson,John Hanfelt,F. Andrew Dorr,Dorraya El‐Ashry,Michael D. Oberst,Удоратина О.В,Jon Holmlund,Shakun Malik	2004	28
11	A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C α, administered as a 21‐day infusion to patients with advanced ovarian carcinoma Cancer ·Ranjana H. Advani,Prema P. Peethambaram,Bert L. Lum,George A. Fisher,Lynn C. Hartmann,Harry J. Long,Joanne Halsey,Jon Holmlund,Andrew Dorr,Branimir I. Šikić	2004	56
12	Applying Antisense Technology Annals of the New York Academy of Sciences ·Jon Holmlund	2003	36
13	Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116)☆ Gynecologic Oncology ·Amit M. Oza,Laurie Elit,K. Swenerton,Wylam Faught,Prafull Ghatage,Masaru Harada,L. McIntosh,Andrew Dorr,Jon Holmlund,Elizabeth A. Eisenhauer	2003	55
14	Antisense Approaches for the Treatment of Cancer Cancer Investigation ·Brett P. Monia,Jon Holmlund,F. Andrew Dorr	2000	30
15	Antisense Oligonucleotides as Inhibitors of Genes That Regulate AP-1: Pharmacology and Clinical Development Antisense and Nucleic Acid Drug Development ·Nicholas M. Dean,Robert A. McKay,Jon Holmlund	1998	6
16	Influence of Interleukin-2 Regimens on Circulating Populations of Lymphocytes After Adoptive Transfer of Anti-CD3-Stimulated T Cells Journal of Immunotherapy ·Brendan D. Curti,Augusto C. Ochoa,Walter J. Urba,W. Gregory Alvord,William C. Kopp,Matthew Robert Ockleton,C.V. Abroal,Stephen P. Creekmore,Barry L. Gause,John E. Janik,Jon Holmlund,Sílvia do Amaral Froemming,Robert G. Fenton,Langdon L. Miller,Mario Sznol,John W. Smith,William H. Sharfman,Dan L. Longo	1996	17
17	Phase II Trial of Interleukin 1 and Indomethacin in Treatment of Metastatic Melanoma JNCI Journal of the National Cancer Institute ·John E. Janik,L.L. Miller,Daniele Longo,Matthew Robert Ockleton,Walter J. Urba,William C. Kopp,Barry L. Gause,Brendan D. Curti,R. G. Fenton,Joost J. Oppenheim,Kevin C. Conlon,Jon Holmlund,Mario Sznol,William H. Sharfman,Ronald G. Steis,Stephen P. Creekmore,W. Gregory Alvord,S. Cogar,John W. Smith	1996	22
18	Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. Journal of Clinical Oncology ·Barry L. Gause,Mario Sznol,William C. Kopp,John E. Janik,John W. Smith,Ronald G. Steis,Walter J. Urba,Hsun-Tong Lin,R. G. Fenton,Zhibo Yan,Jon Holmlund,Kevin C. Conlon,Louis A. VanderMolen,Dan L. Longo	1996	24
19	The Effects of Treatment with Interleukin-1α on Platelet Recovery after High-Dose Carboplatin New England Journal of Medicine ·John W. Smith,J-M Seng,W. Gregory Alvord,John E. Janik,William H. Sharfman,Barry L. Gause,Brendan D. Curti,I. Włdarczyk,Jon Holmlund,耕太木戸,Mario Sznol,Langdon L. Miller,Masanao Shimizu,Joost J. Oppenheim,Fernanda Stapf Pinheiro de Souza,Karen Dvonch Steinmetz,Matthew Robert Ockleton,Walter J. Urba	1993	98
20	Treatment of cancer patients with ex vivo anti-CD3-activated killer cells and interleukin-2. Journal of Clinical Oncology ·Brendan D. Curti,Daniele Longo,Augusto C. Ochoa,Kevin C. Conlon,John W. Smith,W. Gregory Alvord,Stephen P. Creekmore,R. G. Fenton,Barry L. Gause,Jon Holmlund	1993	34

About Jon Holmlund

Jon Holmlund is a scholar working on Otorhinolaryngology, Oncology, Pulmonary and Respiratory Medicine, Hematology and Genetics, having authored 55 papers that have together received 1.7k indexed citations. Recurring topics across this work include Oral health in cancer treatment (11 papers), Head and Neck Cancer Studies (11 papers), Lung Cancer Treatments and Mutations (8 papers), Radiopharmaceutical Chemistry and Applications (6 papers), Lung Cancer Research Studies (6 papers), Colorectal Cancer Treatments and Studies (5 papers), Cancer Treatment and Pharmacology (5 papers) and Cancer therapeutics and mechanisms (4 papers). The work is most often cited by research in Oncology (537 citations), Molecular Biology (1.1k citations), Cancer Research (184 citations), Genetics (126 citations) and Hematology (128 citations). Jon Holmlund has collaborated with scholars based in United States, Canada and Russia. Frequent co-authors include Richard S. Geary, Andrew Dorr, T. Jesse Kwoh, F. Andrew Dorr, John Nemunaitis, Brett P. Monia, Casey Cunningham, Mario Sznol, Lance Leopold and Brian Wood. Their work appears in journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics, Cancer, JNCI Journal of the National Cancer Institute and Blood.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact